Proteios Technology

Proteios empowers the discovery, development and successful commercialization of advanced therapeutics using our proprietary AptaCapture™ isolation platform. Current antibody-based cell isolation methods are slow, costly, and confining innovation and clinical success of cellular therapeutics has plateaued. Proteios has developed an aptamer-based cell isolation platform for the rapid, cost-effective isolation of immune cells. The modular system provides the flexibility to isolate any cell subtype and opens the door for new innovations in cellular therapeutics.

Proteios is developing a portfolio of IP for cell isolation based on proprietary aptamer-based cell isolation platform. Exclusive license for University of Washington (Seattle, WA USA) technology underpinning the current protein purification product offerings.

Cell isolation market is estimated to be $53B by 2033 with CAGR 13%, while the cellular therapeutics market is estimated to be $128B by 2033 with CAGR 30%.

Proteios’ commercialization plan is to utilize a direct sale of preclinical and clinical devices in the US & Europe and enlist a distributor for Asia. Device consumables will utilize an e-commerce direct sales channel.

Company milestones include: 1) commercial launch of five recombinant protein purification kits, 2) preclinical cell isolation beta prototype, 3) clinical cell isolation alpha prototype, and 4) clinical autologous cell therapy manufacturing alpha prototype.

Proteios will be seeking $5M Seed in Q2 2025 to complete beta test of preclinical cell isolation device, ramp-up manufacturing ($3M), and commercial launch ($2M). In Q1 2026, Proteios will seek a $25M Series A to complete development of clinical devices, beta test, submit for regulatory approval, ramp-up manufacturing, and commercial launch.